EmbeddingGemma 2: an open, lightweight multimodal embedding model
deepmind.google·6d ago
AI Engineering
MIT Technology Review·27d ago·5 min read
AI models need more data about biology, and OpenAI is paying to create it
TL;DR
OpenAI is funding a project to acquire data from failed biotech companies, aiming to enhance AI's role in drug approval processes. This initiative seeks to address the critical data shortage hindering medical AI advancements.
✦ Why It Matters
Consider exploring partnerships with biotech firms to access valuable datasets for AI training.
Key Takeaways
- Investigate data acquisition strategies from bankrupt biotech firms.
- Collaborate with organizations like 1Day Sooner for data access.
- Stay informed about OpenAI's funding opportunities in health.
- Utilize AI to analyze complex regulatory processes in drug development.
How It Works
The initiative aims to collect detailed regulatory documents and safety data from bankrupt biotech companies, which are typically trade secrets. By acquiring these datasets, AI models can be trained to better understand the drug approval process, potentially acting as regulatory experts and speeding up the development of new treatments.